Extending levodopa action: COMT inhibition

Neurology

Volumn 50, Issue 6 SUPPL.6, 1998, Pages

  Martínez Martín, Pablo ^a   O'Brien, Christopher F ^b  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^b Colorado Neurological Institute ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3',4' DIHYDROXY 2 METHYLPROPIOPHENONE; 3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 6 FLUORODOPA; ADRENALIN; AMINE OXIDASE (FLAVIN CONTAINING); CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CATECHOLAMINE; DOPAMINE; ENTACAPONE; HOMOVANILLIC ACID; LEVODOPA; N (6 OXO 1H PYRID 2 YL) N',N' DIPROPYLFORMAMIDINE; NEUROTRANSMITTER; NITECAPONE; PYROGALLOL; TOLCAPONE; TROPOLONE;

AREA UNDER THE CURVE; DRUG DEGRADATION; DRUG EFFECT; DRUG METABOLISM; DYSKINESIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0345647071     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.50.6_suppl_6.s27     Document Type: Review

References (60)

1. Lundström K, Salminen M, Jalanko A, Savolainen R, Ulmanen I. Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol 1991;10: 181-189.
2. Axelrod J. Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines. Pharmacol Rev 1966;18:95-113.
3. Calne DB, Reid JL, Vakil SD. Parkinsonism treated with 3-O-methyldopa. Clin Pharmacol Ther 1973;14:386-389.
4. Reches A, Mielke LR, Fahn S. 3-O-Methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology 1982;32:887-888.
5. Muenter MD, Dinapoli RP, Sharpless NS, Tyce GM. 3-O-Methyldopa, L-dopa, and trihexyphenidyl in the treatment of Parkinson's disease. Mayo Clin Proc 1973;48:173-183.
6. Nutt JG, Woodward WR, Gancher ST, Merrick D. 3-O-Methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1987;21:584-588.
7. Fabbrini G, Juncos JL, Mouradian MM, Serrati C, Chase TN. 3-O-Methyldopa and motor fluctuations in Parkinson's disease. Neurology 1987;37:856-859.
8. Feuerstein C, Tanche M, Serre F, et al. Does O-methyldopa play a role in levodopa-induced dyskinesia? Acta Neurol Scand 1977;56:79-82.
9. Guttman M, Léger G, Cedarbaum JM, et al. 3-O-Methyldopa administration does not alter fluorodopa transport into the brain. Ann Neurol 1992;31:638-643.
10. Tolosa E, Valldeoriola F. Mid-stage parkinsonism with mild motor fluctuations. Clin Neuropharmacol 1994;17(suppl 2): 19-31.
11. Quinn N, Marsden CD, Parkes JD. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 1982;1:412-415.
12. Sage JI, Mark MH. The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease. Neurology 1992;42(suppl 1):23-28.
13. LeWitt PA. Levodopa therapeutics: new treatment strategies. Neurology 1993;43(Suppl 6):31-37.
14. Ericsson AD. Potentiation of the L-dopa effect in man by the use of catechol-O-methyltransferase inhibitors. J Neurol Sci 1971;14:193-197.
15. Reches A, Fahn S. 3-O-Methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 1982;12:267-271.
16. Waldmeier PC, Baumann PA, Feldtrauer JJ, et al. CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Naunyn Schmiedebergs Arch Pharmacol 1990;342:305-311.
17. Männistö PT, Tuomainen P, Tuominen RK. Different in vivo properties of three new inhibitors of catechol-O-methyltransferase in the rat. Br J Pharmacol 1992;105:569-574.
18. Kaakkola S, Gordin A, Männistö PT. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen Pharmacol 1994;25:813-824.
19. Törnwall M, Kaakkola S, Tuomainen P, Kask A, Männistö PT. Comparison of two new inhibitors of catechol-O-methylation on striatal dopamine metabolism: a microdialysis study in rats. Br J Pharmacol 1994;112:13-18.
20. 18F]fluoro-L-dopa in rhesus monkey. Nucl Med Biol 1995;22:921-927.
21. Nissinen E, Lindén I-B, Schultz E, Kaakkola S, Männistö PT, Pohto P. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. Eur J Pharmacol 1988;153:263-269.
22. Nissinen E, Lindén I-B, Schultz E, Pohto P. Biochemical and pharmacological properties of a peripherally acting catecholO-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 1992;346:262-266.
23. Cedarbaum JM, Léger G, Guttman M. Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease. Clin Neuropharmacol 1991;14:330-342.
24. 18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology 1992;42:199-203.
25. 18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys. Brain Res 1993;626: 1-13.
26. 18F]fluoro-L-dopa. Eur J Pharmacol 1994;257:53-58.
27. Guttman M, Léger G, Reches A, et al. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov Disord 1993;8:298-304.
28. 18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 1994;44:1292-1297.
29. Kaakkola S, Wurtman RJ. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J Neurochem 1993;60:137-144.
30. Napolitano A, Zürcher G, Da Prada M. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Eur J Pharmacol 1995;273:215-221.
31. Himori N, Mishima K. The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice. Experientia 1994;50:939-942.
32. Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995;57:508-517.
33. Keränen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Pharmacol 1994;46:151-157.
34. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996;19:283-296.
35. Wikberg T, Vuorela A, Ottoila P, Taskinen J. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos 1993; 21:81-92.
36. Sundberg S, Scheinin M, Ojala-Karlsson P, Akkila J, Gordin A. The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition. Eur J Clin Pharmacol 1993;44:287-290.
37. Illi A, Sundberg S, Koulu M, Scheinin M, Heinavaara S, Gordin A. COMT inhibition by high-dose entacapone does not affect haemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int J Clin Pharmacol Ther 1994;32:582-588.
38. Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A. The effect of entacapone on the disposition and haemodynamic effects of intravenous isoproterenol and epinephrine. Clin Pharmacol Ther 1995;58:221-227.
39. Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A. Simultaneous inhibition of catechol-O-methyltransferase and monoamino oxidase A: effects on haemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 1996;59:450-457.
40. Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A. Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions. Eur J Clin Pharmacol 1996;51:273-276.
41. Garrido JM, Mena MA, Correa C, et al. Side effects of the catechol-O-methyl-transferase inhibitor Ro 40-7592 in rabbits. Clin Neuropharmacol 1994;17:270-276.
42. Keränen T, Gordin A, Harjola VP, et al. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers Clin Neuropharmacol 1993;16:145-156.
43. Dingemanse J, Jorga K, Zürcher G, et al. Multiple-dose clinical pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996; 50:47-55.
44. Männistö PT, Kaakkola S. New selective COMT inhibitors: useful adjuncts for Parkinson's disease? Trends Pharmacol Sci 1989;10:54-56.
45. Tuomainen P, Tornwall M, Männistö PT. Minor effect of tolcapone, a catechol-O-methyltransferase inhibitor, on extracellular dopamine levels modified by amphetamine or pargyline: a microdialysis study in anaesthetized rats. Pharmacol Toxicol 1996;78:392-396.
46. Deleu D, Sarre S, Ebinger G, Michotte Y. The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. J Pharmacol Exp Ther 1995;273:1323-1331.
47. Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 1995;18:46-57.
48. Dingemanse J, Jorga K, Zürcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-262.
49. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1993;43:2685-2688.
50. Tohgi H, Abe T, Yamazaki K, Takahashi S, Tsukamoto Y. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Neurosci Lett 1995;192:165-168.
51. Kaakkola S, Teräväinen H, Ahtila S, Rita H, Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994;44:77-80.
52. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:186-189.
53. Ruottinen HM, Rinne UK. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 1996;19:222-233.
54. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one-month, double-blind study in parkinsonian patients with levodopa-related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36-40.
55. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
56. Kurth MC, Adler CH, St. Hilaire M, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997;48:81-87.
57. Davis TL, Roznoski M, Burns RS. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. Mov Disord 1995;10:349-351.
58. Kaakkola S, Teräväinen H, Ahtila S, et al. Entacapone in combination with standard or controlled-release levodopa/ carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. Eur J Neurol 1995;2:341-347.
59. Limousin P, Pollak P, Pfefen JP, Tournier-Gervason CL, Dubuis R, Perret JE. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin Neuropharmacol 1995;3:258-265.
60. Guttman M, and the International Tolcapone Study Group Open long-term evaluation of the safety of tolcapone in Parkinson's disease patients on levodopa containing therapy Mov Disord 1997;12(suppl 1):83.